全球視網膜藥物市場（2023年）：2022-2028年分析

本報告審視了全球視網膜藥物市場，並提供了市場概況，包括未來五年的市場業績預測、未來主要趨勢以及進入市場的 29 家參與者的公司簡介。Masu。

內容

• 對視網膜疾病及其危險因素的思考
• 這些疾病的診斷和治療
• 視網膜醫學和視網膜專家的世界觀
• 市場上的視網膜藥物和生物製劑
• 正在開發的研究藥物
• 開發和營銷視網膜藥物的公司簡介以及擁有臨床前項目的其他公司名單

What's New:

The "2023 Retinal Pharmaceuticals Market Report" features new sales and disease prevalence forecasts through 2028. The report now covers adoption plans for complement inhibitors and new anti-VEGFs by ophthalmologists in the United States and Western Europe, as well as treatment patterns for anti-VEGFs. In addition, it includes IVT injection shares by drug in the United States and Western Europe.

The new report also evaluates more development-stage categories, therapies, and companies.

The "2023 Retinal Pharmaceuticals Market Report" analyzes the market for the treatment of retinal diseases and discusses important trends and key factors for future market success. It examines the market's evolution and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 29 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

The report explores a variety of topics intended to provide depth and context to the understanding of market dynamics in this ophthalmic segment. Our coverage includes:

• Discussions of retinal diseases and their risk factors.

• Diagnosis and treatment of these diseases.

• A global view of retinal care and retina specialists.

• Retinal pharmaceuticals and biologics in the marketplace.

• Investigational agents in the development pipeline.

• Profiles of companies developing and marketing retinal pharmaceuticals, plus a listing of additional companies with preclinical programs.

The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, biosimilars, complement inhibitors expected to enter the marketplace within five years, gene therapies, and others. The report also includes a separate forecast for sustained-drug-delivery devices in retina.

The report delves into the development pipelines of 11 categories of retinal pharmaceuticals:

Author Profile:

Peter Downs

Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China, Europe, and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry newsletter.